Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (4208)	10/21/1997 3:09:00 PM
From: opalapril	Read Replies (2) \| Respond to of 17367

Sad to say, but I am afraid the odds favor only a modest rise in XOMA's stock price if the results are positive and then another drift down to the usual crippled trading range. Other biotechs -- lesser ones, I might add --see a big, permament stock price increase in a short time after a single clinical success. But in XOMa's case, because of its checkered (i.e. "frustrating") past, merely confirming what is already known will not excite Wall Street or the funds that drive the market. Ultimately, the only thing that will convince them and send XOMA soaring is a lucrative long-term manufacturing and marketing agreement with a mega-pharmaceutical company for a specific BPI-derived drug -- in other words, positive proof that XOMA exists to make money, not just provide a test tube playground for woolly headed scientists. What would send the stock reeling, of course, are disappointing clinical results -- which the whole investment world thinks is unlikely to happen.

To: chirodoc who wrote (4208)	10/21/1997 8:52:00 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Regarding Hem trauma results. They are known, but not to us. They arnt being published, just disclosed in a highly regarded forum. According to the company results showed "clear benefit", and IMO are good enough to get in a P3, but int aint in p3 till its in it. Anyways "clear benefit"should mean clear benefit. There is your answer. Memingo has surprise potential and news pending showing perhaps more clear benefit. CF has to start showing something soon, but its too prelim to be meaningful. Liver they want to wrap up, and how that one falls is anyones guess, but since liver clears endotoxin odds are for bpi. Stock behaving nicely.